- Trials with a EudraCT protocol (33)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
33 result(s) found for: Kidney stones.
Displaying page 1 of 2.
EudraCT Number: 2012-001924-37 | Sponsor Protocol Number: HJU1 | Start Date*: 2013-11-05 | |||||||||||
Sponsor Name:Fredericia Hospital | |||||||||||||
Full Title: Relaxation of the ureter during ureterorenoscopy | |||||||||||||
Medical condition: Elevated pressure in the upper urinary tract during ureterorenoscopy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-001519-10 | Sponsor Protocol Number: ALN-GO1-008 | Start Date*: 2022-04-25 | |||||||||||
Sponsor Name:Alnylam Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Lumasiran in Patients with Recurrent Calcium Oxalate Kidney Stone Di... | |||||||||||||
Medical condition: Recurrent calcium oxalate kidney stone disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-004475-13 | Sponsor Protocol Number: 13.031 | Start Date*: 2014-03-05 | |||||||||||
Sponsor Name:Fredericia Hospital | |||||||||||||
Full Title: Pharmacological relaxation of the ureter when using access sheaths during ureterorenoscopy | |||||||||||||
Medical condition: Resistance in the ureter when inserting a ureteral access sheath during ureterorenoscopy. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-019469-26 | Sponsor Protocol Number: pRGF/016/09 | Start Date*: 2010-07-29 |
Sponsor Name:University of Aberdeen [...] | ||
Full Title: Use of drug therapy in the management of symptomatic ureteric stones in hospitalised adults: a multicentre placebo controlled randomised trial of a calcium channel blocker(nifedipine)and an alpha b... | ||
Medical condition: Use of drug therapy in the management of symptomatic ureteric stones in hospitalised adults: multicentre placebo controlled randomised trial of a calcium channel blocker(nifedipine) and an alpha bl... | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2018-003576-12 | Sponsor Protocol Number: OC5-OL-02 | Start Date*: 2019-01-23 | |||||||||||
Sponsor Name:OxThera Intellectual Property AB | |||||||||||||
Full Title: An open-label single-arm treatment extension study to evaluate the long-term efficacy and safety of Oxabact® for patients with primary hyperoxaluria who completed study OC5-DB-02 | |||||||||||||
Medical condition: Primary Hyperoxaluria (PH) | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) GB (GB - no longer in EU/EEA) ES (Prematurely Ended) BE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-005756-32 | Sponsor Protocol Number: HJ2 | Start Date*: 2007-01-18 |
Sponsor Name:Fredericia Hospital | ||
Full Title: Pharmacological modulation of the intrarenal pressure during endourological procedures in the upper urinary tract | ||
Medical condition: Kidney stones Benignant conditions in the upper urinary tract | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DK (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2021-002185-40 | Sponsor Protocol Number: LSH-21-001 | Start Date*: 2022-10-06 |
Sponsor Name:Landspitali - The National University Hospital of Iceland | ||
Full Title: Comparison of the Effect of Allopurinol and Febuxostat on Urinary 2,8-Dihydroxyadenine Excretion and Plasma Levels in Patients with Adenine Phosphoribosyltransferase Deficiency: A Clinical Trial | ||
Medical condition: Adenine phosphoribosyltransferase deficiency | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: IS (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2019-001346-17 | Sponsor Protocol Number: ALN-GO1-005 | Start Date*: 2020-02-20 | |||||||||||
Sponsor Name:Alnylam Pharmaceuticals, Inc. | |||||||||||||
Full Title: ILLUMINATE-C: A Single Arm Study to Evaluate Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Lumasiran in Patients with Advanced Primary Hyperoxaluria Type 1 (PH1) | |||||||||||||
Medical condition: Primary Hyperoxaluria Type 1 (PH1) | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) DE (Completed) GB (GB - no longer in EU/EEA) BE (Trial now transitioned) NL (Ongoing) Outside EU/EEA IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-000921-29 | Sponsor Protocol Number: ALLN-177-302 | Start Date*: 2019-11-12 | |||||||||||
Sponsor Name:Allena Pharmaceuticals, Inc. | |||||||||||||
Full Title: Establishing the Safety and Efficacy of Reloxaliase (Oxalate Decarboxylase) in Patients with Enteric Hyperoxaluria: A Phase III Randomized, Double-Blind, Placebo-Controlled Study (URIROX-2) | |||||||||||||
Medical condition: Enteric Hyperoxaluria | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) AT (Completed) DE (Prematurely Ended) GB (GB - no longer in EU/EEA) PT (Completed) ES (Prematurely Ended) IT (Prematurely Ended) RO (Ongoing) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-006198-98 | Sponsor Protocol Number: 99976 | Start Date*: 2009-10-05 |
Sponsor Name:Isala klinieken Zwolle | ||
Full Title: Pain management in renal colic; The efficacy of continuous intravenous administration of tramadol versus butylscopolamine. A double blinded, randomized placebo controlled, prospective multicenter t... | ||
Medical condition: Renal colic pain based on kidney or ureteric stones in patients of 18 years and older. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2017-000684-33 | Sponsor Protocol Number: OC5-DB-02 | Start Date*: 2017-06-06 | |||||||||||
Sponsor Name:OxThera Intellectual Property AB | |||||||||||||
Full Title: A phase III double-blind, randomized study to evaluate the long-term efficacy and safety of Oxabact® in patients with primary hyperoxaluria | |||||||||||||
Medical condition: Primary Hyperoxaluria (PH) | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) GB (GB - no longer in EU/EEA) NL (Completed) ES (Completed) BE (Completed) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-000975-33 | Sponsor Protocol Number: RDCRN_RKSC_6412 | Start Date*: 2013-11-19 |
Sponsor Name:Landspitali - The National University Hospital of Iceland | ||
Full Title: Novel Assays for the Determination of Urinary 2,8-Dihydroxyadenine and Other Key Urinary Purine Metabolites - Rare Diseases Clinical Research Network Protocol Version 1 | ||
Medical condition: Adenine phosphoribosyltransferase deficiency | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: IS (Completed) | ||
Trial results: View results |
EudraCT Number: 2017-003547-38 | Sponsor Protocol Number: ALLN-177-206 | Start Date*: 2018-07-17 |
Sponsor Name:Allena Pharmaceuticals, Inc. | ||
Full Title: Pilot Study of ALLN-177 in Adult and Pediatric Subjects Aged 12 Years or Older with Enteric or Primary Hyperoxaluria and Hyperoxalemia | ||
Medical condition: Enteric or primary hyperoxaluria and hyperoxalemia | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) GB (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2015-004770-16 | Sponsor Protocol Number: PNL_protocol_v01 | Start Date*: 2016-01-04 | |||||||||||
Sponsor Name:Jens Børglum | |||||||||||||
Full Title: Ultrasoundguided Transmuscular Quadratus Lumborum(TQL) block for percutaneous nephrolithotomy (PNL) - a randomized controlled trial | |||||||||||||
Medical condition: The postoperative pain after percutaneous nephrolithotomy(PNL) operation. Our one year retrospective study of patients treated with PNL, revealed that, 71% of all patients undergoing PNL operation... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-004014-17 | Sponsor Protocol Number: ALN-GO1-004 | Start Date*: 2019-03-01 | |||||||||||
Sponsor Name:Alnylam Pharmaceuticals, Inc. | |||||||||||||
Full Title: ILLUMINATE-B: An Open-Label Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Lumasiran in Infants and Young Children with Primary Hyperoxaluria Type 1 | |||||||||||||
Medical condition: Primary Hyperoxaluria Type 1 (PH1) | |||||||||||||
|
|||||||||||||
Population Age: Newborns, Infants and toddlers, Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) FR (Completed) DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-003098-91 | Sponsor Protocol Number: DCR-PHXC-201 | Start Date*: 2019-03-05 | |||||||||||
Sponsor Name:Dicerna Pharmaceuticals Inc | |||||||||||||
Full Title: A Phase 2 Placebo-Controlled, Double-Blind, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of DCR-PHXC Solution for Injection (subcutaneous use) in Patients with Primary Hyper... | |||||||||||||
Medical condition: Primary Hyperoxaluria | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) GB (GB - no longer in EU/EEA) DE (Completed) NL (Completed) ES (Ongoing) PL (Completed) IT (Completed) RO (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-004352-33 | Sponsor Protocol Number: ALLN-177-301 | Start Date*: 2018-07-18 |
Sponsor Name:Allena Pharmaceuticals, Inc. | ||
Full Title: Evaluate the Safety and Efficacy of ALLN-177 in Patients with Enteric Hyperoxaluria: A Phase III Randomized, Placebo-Controlled Study | ||
Medical condition: Enteric Hyperoxaluria | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) ES (Completed) GB (Completed) IT (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2018-001981-40 | Sponsor Protocol Number: ALN-GO1-003 | Start Date*: 2018-11-20 | |||||||||||
Sponsor Name:Alnylam Pharmaceuticals, Inc. | |||||||||||||
Full Title: ILLUMINATE-A: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study with an Extended Dosing Period to Evaluate the Efficacy and Safety of Lumasiran in Children and Adults with Primary Hypero... | |||||||||||||
Medical condition: Primary Hyperoxaluria Type 1 (PH1) | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) FR (Completed) DE (Completed) NL (Ongoing) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-003134-24 | Sponsor Protocol Number: ALN-GO1-002 | Start Date*: 2017-12-28 | |||||||||||
Sponsor Name:Alnylam Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Phase 2, Multicenter, Open-Label, Extension Study to Evaluate the Long-Term Administration of ALN-GO1 in Patients with Primary Hyperoxaluria Type 1 | |||||||||||||
Medical condition: Primary Hyperoxaluria Type 1 (PH1) | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) GB (GB - no longer in EU/EEA) NL (Ongoing) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-000308-82 | Sponsor Protocol Number: oxalate01 | Start Date*: 2017-02-08 |
Sponsor Name:Universitair Ziekenhuis Brussel | ||
Full Title: Lanthanum Carbonate (Fosrenol®) to reduce oxalate excretion in patients with secondary hyperoxaluria and nephrolithiasis: a short-term, prospective, open-label, efficacy and safety clinical trial | ||
Medical condition: Urolithiasis and secondary hyperoxaluria | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Completed) | ||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
